Article
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Cancer cell - 10 Jul 2012
Berry Teeara, Luther William, Bhatnagar Namrata, Jamin Yann, Poon Evon, Sanda Takaomi, Pei Desheng, Sharma Bandana, Vetharoy Winston R, Hallsworth Albert, Ahmad Zai, Barker Karen, Moreau Lisa, Webber Hannah, Wang Wenchao, Liu Qingsong, Perez-Atayde Antonio, Rodig Scott, Cheung Nai-Kong, Raynaud Florence, Hallberg Bengt, Robinson Simon P, Gray Nathanael S, Pearson Andrew D J, Eccles Suzanne A, Chesler Louis, George Rani E
Abstract excerpt
The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALK(F1174L) in the neural crest. Compared to ALK(F1174L) and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.